These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 9488536)

  • 21. [Optimization of cholesterol reduction principles and clinical results of dual inhibition].
    von Hodenberg E
    Internist (Berl); 2005 May; 46 Suppl 1():S18-23. PubMed ID: 15834540
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Critical evaluation of indications for lipid reduction. Cholesterol value updated--risk counts (interview by Dr. Kirsten Westphal)].
    Motz W
    MMW Fortschr Med; 2003 Oct; 145(41):48. PubMed ID: 14655487
    [No Abstract]   [Full Text] [Related]  

  • 23. [Milestone in the treatment of diabetic dyslipidemia: the DAIS Study].
    Forster T
    Orv Hetil; 2001 Jul; 142(29):1588-9. PubMed ID: 11494751
    [No Abstract]   [Full Text] [Related]  

  • 24. Effect of statin therapy on total mortality. Trial in a more varied population.
    Alkhenizan A
    Can Fam Physician; 2003 Jun; 49():757-9. PubMed ID: 12836863
    [No Abstract]   [Full Text] [Related]  

  • 25. [Treatment of dyslipidemia in the secondary prevention of coronary artery disease].
    Syvänne M
    Duodecim; 1998; 114(15):1503-8. PubMed ID: 11552239
    [No Abstract]   [Full Text] [Related]  

  • 26. Pharmacotherapy of hyperlipidemia in pediatric heart transplant recipients: current practice and future directions.
    Chin C; Bernstein D
    Paediatr Drugs; 2005; 7(6):391-6. PubMed ID: 16356026
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The antilipemic effectiveness of aluminium clofibrate on hyperlipidemic patients with or without diabetes mellitus.
    Lam HC; Li SH; Wang JT; Tang KT; Ho LT
    Zhonghua Yi Xue Za Zhi (Taipei); 1987 Nov; 40(5):463-70. PubMed ID: 3332236
    [No Abstract]   [Full Text] [Related]  

  • 28. [Helsinki Heart Study].
    Sekiya M; Ishibashi S
    Nihon Rinsho; 2001 Mar; 59 Suppl 3():404-9. PubMed ID: 11347103
    [No Abstract]   [Full Text] [Related]  

  • 29. Relative risk reduction versus number needed to treat as measures of lipid-lowering trial results.
    Moriarty PM
    Am J Cardiol; 1998 Aug; 82(4):505-7. PubMed ID: 9723640
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Assessment and management of vascular disease risk in patients with chronic kidney disease.
    Brown WV; Bakris G; Lerma E; Chertow G
    J Clin Lipidol; 2011; 5(4):251-60. PubMed ID: 21784369
    [No Abstract]   [Full Text] [Related]  

  • 31. [Hyperlipidemia and arteriosclerosis].
    Mabuchi H
    Nihon Naika Gakkai Zasshi; 1998 May; 87(5):950-7. PubMed ID: 9648450
    [No Abstract]   [Full Text] [Related]  

  • 32. [Hypolipemic therapy in peripheral arterial diseases: reasons of its clinical use].
    Balbarini A; Coli S
    Cardiologia; 1999 Feb; 44(2):137-45. PubMed ID: 10208050
    [No Abstract]   [Full Text] [Related]  

  • 33. Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia. Report of the Program on the Surgical Control of the Hyperlipidemias (POSCH).
    Buchwald H; Varco RL; Matts JP; Long JM; Fitch LL; Campbell GS; Pearce MB; Yellin AE; Edmiston WA; Smink RD
    N Engl J Med; 1990 Oct; 323(14):946-55. PubMed ID: 2205799
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The need for a different cholesterol lowering drug.
    Steiner G
    Can J Clin Pharmacol; 2003; 10 Suppl A():4A-6A. PubMed ID: 14571300
    [No Abstract]   [Full Text] [Related]  

  • 35. Impact of cholesterol reduction on peripheral arterial disease in the Program on the Surgical Control of the Hyperlipidemias (POSCH).
    Buchwald H; Bourdages HR; Campos CT; Nguyen P; Williams SE; Boen JR
    Surgery; 1996 Oct; 120(4):672-9. PubMed ID: 8862377
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Perception of quality of life before and after disclosure of trial results: a report from the Program on the Surgical Control of the Hyperlipidemias (POSCH).
    Buchwald H; Fitch LL; Matts JP; Johnson JW; Hansen BJ; Stuenkel MR; Brooks HB
    Control Clin Trials; 1993 Dec; 14(6):500-10. PubMed ID: 8119065
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Overviews of fibrate].
    Tada N
    Nihon Rinsho; 2001 Mar; 59 Suppl 3():609-17. PubMed ID: 11347141
    [No Abstract]   [Full Text] [Related]  

  • 38. [Hypolipidemic agents and their indication].
    Teramoto T
    Nihon Rinsho; 2001 Mar; 59 Suppl 3():559-65. PubMed ID: 11347132
    [No Abstract]   [Full Text] [Related]  

  • 39. Primary prevention of ischaemic heart disease with lipid-lowering drugs.
    Lancet; 1988 Feb; 1(8581):333-4. PubMed ID: 2893141
    [No Abstract]   [Full Text] [Related]  

  • 40. The POSCH data processing experience. The problem of metadata.
    Long JM
    J Med Syst; 1986 Apr; 10(2):173-83. PubMed ID: 3528373
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.